Inrebic

Fedratinib, the active ingredient in Inrebic, is a JAK2 inhibitor presented as a tablet for oral use. It is approved in the European Union for the treatment of primary myelofibrosis and for post‑polycythemia vera or post‑essential thrombocythemia myelofibrosis in adult patients.

GNH USA supplies Inrebic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres and pharmacies worldwide, ensuring quality and regulatory compliance. Our distribution network reaches major treatment facilities across Europe, Asia and the Americas, providing reliable access to this targeted therapy.

Inrebic (fedratinib) is indicated for the treatment of myeloproliferative neoplasms that involve abnormal JAK2 signaling.

Primary myelofibrosis: reduces spleen volume, alleviates constitutional symptoms and may improve blood counts in patients with this primary disease. Post‑polycythemia vera myelofibrosis: mitigates disease progression, lessens splenomegaly and helps control anemia and other myelofibrosis‑related symptoms. Post‑essential thrombocythemia myelofibrosis: helps manage splenomegaly, reduces symptom burden and supports hematologic stability in patients who have transformed from essential thrombocythemia.

Fedratinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: loose stools that may be mild to moderate. - Nausea: feeling of sickness often occurring after dosing. - Fatigue: persistent tiredness affecting daily activities. - Anemia: reduced red blood cell count leading to weakness.

Serious or Rare Side Effects: - Wernicke encephalopathy: neurological disorder associated with thiamine deficiency. - Severe infections: opportunistic bacterial or fungal infections requiring medical attention. - Hepatotoxicity: elevated liver enzymes indicating potential liver injury.

When using Inrebic, several safety measures should be observed.

Monitor blood counts: regular CBC testing to detect anemia or thrombocytopenia. Assess liver function: periodic liver enzyme tests for hepatotoxicity. Evaluate for thiamine deficiency: consider supplementation to prevent Wernicke encephalopathy. Avoid use in patients with active severe infections. Pregnancy and lactation: use only if potential benefit outweighs risk; data are limited. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Fedratinib can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase fedratinib plasma levels, raising toxicity risk. - Concomitant use with other JAK inhibitors: can cause additive myelosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce fedratinib efficacy. - Anticoagulants: increased bleeding risk due to possible thrombocytopenia. - Live vaccines: potential reduced efficacy; assess timing relative to therapy.